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Objectives: The aim of this study was to evaluate the effect of SLPI on the growth and
biological processes of Candida albicans.
Methods: Two C. albicans strains were used in this study, a clinical isolate resistant to
fluconazole (PRI) and a reference strain ATCC 24433. The minimal inhibitory concentration
(MIC) was determined according to the CLSI methodology. The influence of SLPI on secreted
serine proteinase activities (SSP) was measured by the cleavage of specific substrate, and
surface hydrophobicity was determined by the aqueous-hydrocarbon biphasic separation
method. Flow cytometry was performed to investigate receptors for SLPI and variations in
the cell wall mannoprotein expression. Interaction between yeast and epithelium was
assessed using the MA-104 cells lineage. Ultrastructure was analyzed by transmission
electron microscopy (TEM).
Results: MIC values were calculated as 18 and 18.9 mM for the PRI and ATCC 24433, respec-
tively. SSP activity was reduced by 48.8% by 18 mM of SLPI and cell surface hydrophobicity
increased by 11.1%. Flow cytometry suggest the existence of SLPI binding sites on the surface
of the yeast. Results showed a reduction in the expression of mannoproteins in 20.8% by the
cells treated with 80 mM of SLPI, and 18 mM reduced the adhesion of yeasts to mammalian
cells in 60.1%. TEM revealed ultrastructural changes in cells treated with 80 mM of SLPI, such
as the presence of membrane-like structures within the cytoplasm.
Conclusions: SLPI exerts a significant influence on C. albicans viability and biological pro-
cesses. Considering its constitutive and physiologic features, SLPI may become a promising
tool for the development of new methodologies for the treatment and control of candidiasis.
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Candidiasis is a major opportunistic fungal infection in
humans and its incidence has increased steadily over the
last two decades due to the increasing number of susceptible
individuals, such as transplant patients and HIV + indivi-
duals,1 as well as the population ageing and the extensive use
of aggressive antimicrobial and chemotherapeutic agents.2–4
This situation is further aggravated due to the limited number
of antifungal drugs commercially available, that does not
allow an efficient control of the infection caused by this fungi.5
For many years, fungal infections were treated with polyene
compounds (Nystatin and Amphotericin B), despite their high
toxicity. In the early 90s, the development of first generation
triazoles (fluconazole and itraconazole) changed the epidemi-
ology of candidiasis by offering new options for prevention
and treatment.6 However, the extensive use of these new
antifungal agents has resulted in resistant strains, which now
creates urgency for the development of new treatment
strategies.7,8
Human candidiasis infections can range from a mild
disease to a severe systemic infection that can be fatal.9 Such
variations occur, in large part, due to virulence factors that can
determine the course of the infection. In candidiasis, these
factors are responsible for the success of the colonization or
infection in the host. Candida albicans, in particular, has
developed an effective set of virulence attributes and specific
strategies that can determine the course of infection.10,11
Although there are many virulence factors that have been
attributed to C. albicans, hydrophobicity; adherence to the host
tissues; morphological conversion to the filamentous form
(dimorphism); recognition of surface molecules and enzymes
production are considered the most important issues to
date.12–14 Therefore, considering the role of extracellular
enzymes in the pathogenesis of candidiasis, the therapeutic
use of protease inhibitors could act to reduce the virulence of
C. albicans.15
The secreted leucocyte protease inhibitor (SLPI) is a
cationic, non glycosylated protein, consisting of 107 amino
acids with a low molecular weight (11.7 kDa),16–19 able to
inhibit the activity of a large number of serine proteases.17,20,21
SLPI can be found in several mucosal secretions, such as
saliva, milk and semen, in different concentrations, ranging
from 2.0 mM in saliva22–25 to 80 mM in seminal fluid.26 The
therapeutic potential of SLPI was demonstrated ‘‘in vitro’’
when applied on induced epidermal lesions, which resulted in
the reduction of the lesion size, the tissue repair time and
inflammation.27,28 In addition, SLPI antimicrobial features
have already been reported.29–32 Therefore, the enzymatic
inhibitory features of this protein associated to its antifungal
activity suggest its potential for the development of new
therapeutic strategies against candidiasis. Considering this,
this study aimed to evaluate the antifungal potential of SLPI on
C. albicans biological processes, which may contributes to the
development of new strategies for therapeutics and prophy-
laxis of candidiasis.
This study shows for the first time the ability of SLPI to
modulate different virulence factors, such as: the proteolytic
activity, hydrophobicity, adhesion to epithelium andmannoprotein expression on C. albicans. These factors were
particularly selected due to its essential role in the very early
stages of the infections, providing the installation of the
disease. In addition, the ultrastructural changes that this
protein causes on the yeast were evaluated by TEM.
2. Materials and methods
2.1. Strains and culture conditions
Despite the emerging shift in the aetiology of candidiasis,
C. albicans remains the most prevalent species in mucosal
infections,33–36 skin infections37 and in nosocomial candide-
mia.38 Thus, two strains of C. albicans were chosen to be
evaluated in this work. One clinical strain resistant to
fluconazole, which was isolated from the oral mucosal of an
HIV(+) patient, namely PRI,39,40 that was used in all experi-
ments, and the ATCC 24433 reference strain, which was used
in the MIC and in the minimal fungicidal concentration (MFC)
assays. Before any experimental procedures, both strains were
subcultured into Brain Heart Infusion (BHI) broth and
incubated at 37 8C for 48 h for the yeasts to reach the
exponential growing phase.
2.2. Recombinant protein
Recombinant SLPI protein and anti-hSLPI antibody were
purchased from R&D System1 (Minneapolis, USA) and
reconstituted in phosphate-buffered saline PBS 10 mM, pH
7.2 at 25 8C.
2.3. MIC and MFC
SLPI MIC was determined according to the M27-A2 methodol-
ogy for microdilution. Serial protein dilutions were prepared in
the range from 80 to 0.62 mM, and fluconazole and nystatin
were used as control. Microtitre plates were evaluated
spectrophotometrically (600 nm), and the results were ana-
lyzed through the linear equation obtained by dispersion
analysis in Microsoft Excel1. The minimum concentration
able to inhibit yeast growth completely and 50% were defined
as MIC and IC50, respectively. MFC was calculated by sub-
culturing 10 mL of each well onto Sabouraud dextrose agar
(SDA) medium in Petri dishes, and incubated at 37 8C for 24 h.
The lowest protein concentration able to decrease yeast
viability by 99.9% was considered to be MFC.
2.4. Proteolytic activity
The inhibitory function of SLPI towards the proteolytic activity
of secreted serine proteinases from the C. albicans clinical
strain was evaluated by the cleavage of the fluorogenic
substrate Z-Phe-Arg-4-methoxy-b-naphthylamide (Sigma
Aldrich1, St. Louis, USA). After a 48 h incubation in BHI
medium, yeast cells were harvested by centrifugation for
8 min at 4 8C, the supernatant was filtered in a Millipore1
(Billerica, MA, USA) membrane 0.22 mm and concentrated by
ultrafiltration with an exclusion membrane of 10 kDa, for 7 h
at 4 8C resulting in a 30 concentrated solution.8 The
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reaction buffer containing sodium acetate 0.1 M, pH 5.0 and
2.5 mL of the fluorogenic substrate Z-Phe-Arg-4-methoxy-
naphthylamide and incubated at 37 8C for 1 h with different
concentrations of SLPI (2.0 and 18 mM) that were added during
the hydrolysis process. The reaction was stopped by the
addition of 150 mL of trichloroacetic acid 5%. Substrate
cleavage was fluorometrically read at wavelengths of 380
and 450 nm for fluorescence excitation and emission, respec-
tively.41
2.5. Cell surface hydrophobicity (CSH)
CSH was determined by the aqueous-hydrocarbon biphasic
hydrophobicity assay. Briefly, 1  107 cells were incubated in
80 mM of SLPI (highest physiologic concentration) for 6 h at
37 8C, washed in cold deionized water and suspended in
phosphate urea magnesium (PUM) buffer, pH 7.1, and optical
density was adjusted to 0.400 at 600 nm. Yeast samples
(1.2 mL) were added to 300 mL of cyclohexane in borosilicate
glass tubes and vigorously vortexed for 3 min. After decant-
ing, the aqueous portion was measured at the same
wavelength. The percentage difference between readings of
the aqueous phases before and after cyclohexane addition
was considered to be the hydrophobicity value of the cell
population.42
2.6. SLPI binding to C. albicans wall
Flow cytometry analysis was carried out in order to investigate
ligants for SLPI on the surface of the C. albicans clinical strain.
Briefly, 106 cells were washed in PBS 10 mM, pH 7.2, fixed in
paraformaldehyde 4%, blocked with bovine serum albumin
(BSA) 5%, and incubated with 2 (lowest physiological concen-
tration) or 9 mM of SLPI for 90 min at 25 8C. Cells were then
washed and incubated with 10 mg/L of SLPI antibody (anti-
hSLPI Affinity Purified Goat IgG, R&D System1 Minneapolis,
USA) for 1 h, and incubated with secondary antibody anti goat
IgG conjugated to fluorescein isothiocyanate (FITC) (Sigma
Aldrich1 St. Louis, USA), in a 1:1000 dilution. Yeast cells (10 000
events) were evaluated in a flow cytometer EPICS ELITE
(Coulter Electronics, Hialeah, FL, USA) equipped with 15 mW
argon laser at a wavelength of 488 nm, and results were
analyzed using the WinMDI software version 2.8. Control cells
(cells that were only washed and fixed) were used to determine
autofluorescence.
2.7. Cell wall mannoprotein expression
In order to evaluate variations in the presence or expression of
cell wall mannoproteins, flow cytometry analysis was carried
out. Yeasts cells (1  107) were incubated with 9.0 (IC50) and
80 mM of SLPI for 6 h at 37 8C. After incubation, cells were
washed in PBS 10 mM, pH 7.2, fixed in paraformaldehyde 4%,
blocked with BSA 5%, and incubated with FITC labelled
Concanavalin-A (Sigma Aldrich1 St. Louis, USA), (2 mg/ml)
in a 1:500 dilution. Yeasts were washed and 10 000 events were
acquired for each analysis in an EPICS ELITE1 flow cytometer
(Coulter Electronics, Hialeah, FL, USA) equipped with a 15 mW
argon laser at a wavelength of 488 nm.2.8. Adhesion of C. albicans to epithelial cell
Epithelial cells from monkey kidneys (MA 104) were sus-
pended in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% foetal calf serum (FCS), and 1  105
cells were placed onto glass coverslips in a 24 well culture plate
which was incubated at 37 8C in a 5% CO2 humidified
atmosphere for 24 h. Yeast cells were incubated with the
mammal cells at a 10:1 ratio in DMEM with or without 18 mM
(MIC) of SLPI for 90 min at 37 8C. Un-adhered yeasts were
removed by extensive washes with PBS 10 mM, 7.2 pH, and
coverslips were fixed with Bouin, stained with Giemsa,
dehydrated in acetone and xylol and then mounted on
Permount1 (Fisher Chemicals, Leicestershire, UK). The num-
ber of associated yeasts per 100 epithelial cells was estimated
by counting under optical microscopy at a 1000 magnifica-
tion with an Axioplan 21microscope (Zeiss, Jena, Germany).12
2.9. Ultrastructure
To evaluate possible ultrastructural changes caused by SLPI,
the yeasts were treated and analyzed by transmission
electronic microscopy (TEM). The cells (1  107) were incubat-
ed with 9.0 and 80 mM of SLPI for 6 h at 37 8C, washed in PBS
10 mM, pH 7.2 and fixed in 2.5% glutaraldehyde in sodium
cacodylate buffer 0.1 M, pH 7.2 for 1 h. Fixed samples were
washed and post-fixed in 1% osmium tetroxide in sodium
cacodylate buffer 0.1 M, pH 7.2 containing 0.8% potassium
ferrocyanide and 5 mM of CaCl2. Dehydration was carried out
by increasing concentrations of acetone, and samples were
embedded in epoxy resin to make the blocks which were
polymerized at 60 8C for 72 h. Blocks were cut on an
ultramicrotome and sections were placed on copper grids
and contrasted in saturated uranyl acetate and lead citrate
solution. Images were finally analyzed in a transmission
electron microscope EM 9001 (Zeiss, Oberkochen, Germany).
2.10. Statistical analyses
Flow cytometry final results were considered to be the
representation of four independent experiments. All others
experiments were performed at least in triplicate and results
were expressed as mean  standard deviation. Data were
analyzed by the Student’s t-test paired, and p values lower
than 0.05 were considered significant.
3. Results
3.1. MIC and MFC
The MIC data of the clinical isolate and ATCC strain of C.
albicans are summarized in Table 1. The results show that SLPI
was able to inhibit yeast growth in both strains in similar
concentrations. Equivalence between molarity and weight/
volume concentrations was registered as well, and MIC and
IC50 were equivalent to 18 and 18.9 and 9.9 and 9.4 mM for the
clinical isolate and ATCC 24433 strains, respectively. MFC for
both strains were calculated as 20 mM, suggesting primarily a
fungicidal activity.
Table 1 – MIC and IC50 of SLPI, fluconazole and nystatin assessed on C. albicans ATCC 24433 and clinical isolate, according
to the CLSI M-27A2 protocol. Cell growth was measured spectrophotometrically (600 nm).
C. albicans SLPI (mM) Fluconazole (mg/L) Nystatin (mg/L)
MIC IC50 MIC IC50 MIC IC50
Clinical isolate 18  2.6 9.9  1.2 >128 >128 9.67  0.5 4.06  0.7
ATCC 24433 18.9  0.5 9.4  0.2 2.81  2.7 1.51  1.8 nt nt
nt = not tested.
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The proteolytic activity profile of secreted serine proteases
released by the clinical isolate in the presence of different SLPI
concentrations are summarized in Fig. 1. The figure shows
that the minimal physiologic concentration (2.0 mM) and MIC
(18 mM) of SLPI were able to inhibit the proteolytic activity of
serine protease secreted by C. albicans in 37.1% and 48.4%,
respectively.
3.3. Hydrophobicity
Cell surface hydrophobicity was determined by the aqueous-
hydrocarbon biphasic partitioning assay and revealed that
when the yeasts were incubated with the highest physiologic
concentration (80 mM) of SLPI for 6 h at 37 8C, CSH reached
27.2%, whereas CSH was 16.1% in the incubation cells without
SLPI, indicating an increase of 11.1% in the yeast CHS after SLPI
treatment.
3.4. Surface receptors for SLPI
The histogram presented in Fig. 2 demonstrates that SLPI was
able to recognize specific molecules on the surface of C.
albicans. Fluorescence peaks moved to the right when yeast
cells were treated with the lowest physiological concentration
of SLPI 2 mM (Fig. 2A) and 9 mM of SLPI (Fig. 2B). However this
latter incubation shows a greater peak displacement, com-0
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Fig. 1 – Effect of SLPI on proteolytic activity of serine
proteases secreted by C. albicans. The concentrated
supernatant was diluted with buffer containing the
fluorogenic substrate in the absence (CTRL) or presence of
2.0 and 18 mM SLPI. The percentage difference between the
fluorometric readings was considered the inhibition of
proteolytic activity p < 0.001 (*); p = 0.001 (**).pared to the first one, pointing to a higher level of recognition.
For confirmation, arbitrary fluorescent units (AFU) were
measured, and they showed an increase in fluorescence
emission of 21.1% and 70% when the yeasts were incubated
with 2 and 9 mM of SLPI, respectively.
3.5. Cell wall mannoprotein expression
Flow cytometry analysis using concanavalin-A (con-A) as a
probe for mannoproteins revealed that treatment with the IC50
of SLPI (9.0 mM) did not alter the expression of receptors for the
lectin on the surface of C. albicans (Fig. 3). However, when cells
were incubated with the highest physiologic concentration
(80 mM) of SLPI, the flow cytometry analysis revealed a
decrease in the expression of mannoproteins on the cell wall
of the yeast. Considering only AFUs, there was a decrease of
20.8% in the fluorescence emitted by yeast cells treated with
80 mM of SLPI, while no shrinkage was observed in the 9.0 mM
incubation.
3.6. Adhesion of C. albicans to epithelial cells
The influence of 18 mM of SLPI on the interaction between the
clinical strain and MA 104 is demonstrated in Fig. 4. SLPI was
able to reduce the association index by 60.1%, as shown in
Fig. 4(a). Representative images of the interaction process are
shown in Fig. 4(b), where a clear distinction between the
interaction patterns can be seen, strengthening the results of
quantitative analysis.
3.7. Ultrastructure
Transmission electron microscopy revealed ultrastructural
changes in cells treated with 9.0 (data not shown) and 80 mM of
SLPI (Fig. 5). Treatment with 80 mM SLPI caused cell deflation
and structural changes such as the presence of disorganized
membrane structures within the cytoplasmatic compartment.
4. Discussion
Growth inhibition can contribute substantially to control
fungal infections, since the ability to limit the proliferation of
rapidly growing fungi can decrease the onset of the disease in
susceptible patients.43 Fluconazole displays linear pharmaco-
kinetics in dosages that can reach 50–800 mg/day, it has a high
bioavailability, and low binding to circulating proteins, which
provides an easy and quick access to patient’s tissues.3 Cutoff
points that determine the resistance or susceptibility of C.
albicans to fluconazole are well established and MIC values
Fig. 2 – Analysis by flow cytometry showing binding of SLPI to the surface of C. albicans. Yeasts were incubated with 2.0 mM
SLPI (a), or 9.0 mM of SLPI (b) for 90 min, followed by incubation with anti-hSLPI antibody and FITC-labelled secondary
antibody (empty peaks). Autofluorescence was given by control cells that were not incubated with the protein and are
represented by peaks filled in red. Arbitrary fluorescent units (AFU) were quantified and are represented by the figure inset.
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or susceptible to this drug, respectively.44 In this study, the
evaluation of MIC showed distinct fluconazole values for the
two strains of C. albicans, as expected. However, SLPI values
were similar for both strains suggesting that the resistance
mechanisms to fluconazole from the PRI strain were unable to
affect SLPI activity. In fact, an MFS efflux pump was recently
identified in the PRI strain as the main cause of its fluconazole
resistance.40 Therefore, similar MIC values for both suscepti-
ble and PRI strain makes us believe that this efflux mechanism
may be ineffective against SLPI activity. Anyway, resistance to
antifungal drugs has particular importance considering the
limited number of commercially available drugs.2 Thus, any
new therapy able to circumvent this situation must be
considered relevant.
SLPI MIC values for both strains were higher than 17 mM,
which remains within the range of physiological secretion.26
Therefore, considering its constitutive features, it is likely that
an exogenous administration of SLPI could fulfil its antifungal
biological role without any adverse effects on the patient.45
The administration of 17 mM of recombinant SLPI, by
aspiration, on the bronchopulmonary epithelium of patients
with cystic fibrosis reduced proteolytic activity and the
expression of interleukin 8 (IL-8) providing a significant
improvement in the inflammation.46 The inhibitory values
obtained in this study, although high, seem promising and
reinforce the idea of using SLPI as a possible therapeutic
alternative.Regarding growth and viability; the results showed that
MIC and MFC values were similar, pointing primarily to a
fungicidal activity. Clinically, the selection criteria for antimi-
crobial drugs are universal, and postulate that whenever there
is an option, the chosen drug must be microbicidal in the first
place,47 reinforcing the potential of SLPI as a therapeutic
option in the future.
The secreted protease activities of C. albicans have been
associated with the increase in the virulence of this organism;
therefore, the therapeutic use of protease inhibitors has been
suggested as a potential alternative for the control and
management of candidiasis.11 The superfamily of subtilisin-
like serine are reportedly responsible for activating protein
precursors in Saccharomyces cerevisiae and C. albicans.48 In these
two genuses, a similar proenzyme prototype is Kex2p, which is
a cytoplasmic serine protease involved in the expression of
some pivotal virulence factors in C. albicans, including
morphological differentiation and the clearance of extracellu-
lar proteases, which are factors considered essential to a
successful infection.12,49,50 In fact, this study demonstrated
that the physiologic concentrations of SLPI were able to inhibit
significantly the proteolytic activity of serine proteases
secreted by C. albicans.
Adhesive interactions are considered the initial step that
leads to the establishment of infections caused by any
microorganism, including Candida spp.51,52 The presence of
SLPI during the interaction process between epithelial cells
and C. albicans reduced it by more than 60%. Epithelial invasion
Fig. 3 – Histogram showing the binding of concanavalin A labelled with FITC to the surface of C. albicans, after treatment with
9.0 mM (a) or 80 mM (b) of SLPI for 6 h at 37 8C. Autofluorescence was given by not incubated nor labelled cells and is represented
by red empty lines. Treated cells are represented by green filled peaks while untreated cells are expressed by solid empty
black lines. Both treated and untreated cells were incubated with FITC labelled concanavalin A for 1 h and analyzed by flow
cytometry. Arbitrary fluorescent units (AFU) were quantified, as well, and are represented by the figure inset.
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normally follows two different mechanisms: an active pene-
tration, where C. albicans hyphae or germ tube elongates and
pushes itself physically into the host cell,53 and penetrationFig. 4 – Effect of SLPI protein on the interaction between C. albica
interaction reduced the adhesion process significantly (a). Repr
albicans adhered to epithelial cells in both treated and control f
respectively). (*) p = 0.003.by endocytosis, where adhesins bind to epithelial cell
receptors and activate proper endocytosis machinery.54
In fact, the role of serine proteinases in the adhesion process
is considered crucial, as its inhibition by classical inhibitors,ns and epithelial cells. The presence of 18 mM of SLPI during
esentative images (b) are shown, and arrows point to C.
ields. Magnification 400T and 1000T (up and lower boxes,
Fig. 5 – Transmission electron microscopy of C. albicans untreated cells (A and B) and cells treated with 80 mM of SLPI (C–H).
Control cells show regular contour and electrondense cytoplasm (A) and a fungal cell wall with different layers
electrondensities (B). Treated cells present hollow cytoplasm (C–E), and irregular membrane structures along the
cytoplasmic membrane (arrows in D and E), The insets 1 and 2 in D correspond to F and G, respectively, and the inset in the
E corresponds to H. Bars represent 0.2 mm (B, F, G and H) and 1.0 mm (A, C, D and E).
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to downregulate association indexes to similar levels.12
Histopathologically, the interaction process between fungal
and epithelium can be considered a dynamic process that
relies on proper features from the host, such as ageing or
immunosuppression, and from the yeast such as hydropho-
bicity, positive net charge, presence of pathogen-associated
molecular patterns (PAMP), and exposing of mannoproteins,
among others.55
CSH has been considered a non biological factor strongly
related to the adhesion of fungal cells to host tissues,56–58 and
to the yeast resistance to phagocytosis by polymorphonuclear
cells.59 This feature probably occurs due to the presence of
hydrophobic proteins that can promote the binding to
extracellular matrix components. But it is also possible that
CSH could facilitate specific interactions between receptors
and their ligants on the surface of the fungus.60 In 2004,
Hazen59 described for the first time, a hydrophobic surface
protein constitutive of C. albicans namely CSH1p, which is
expressed independently of environmental conditions,culture or cell morphology. Recently and using a similar
methodology, it was reported that sub-inhibitory concentra-
tions of gluconate chlorhexidine were able to reduce C. albicans
CSH in a dose dependent manner regardless of a patient’s
characteristics such as diabetic, asthmatic or smoker.61
However, this study revealed an increase of 11.1% in CSH
after treatment with 80 mM of SLPI. The results obtained by
Ellepola and co-workers (2013)61 could be explained by
chlorhexidine pharmacodynamics characteristics, because
this compound acts directly on the cell membrane as a
cationic detergent, while SLPI may be evolved in other
biological processes, such as proteinases inhibition.19
The surface of C. albicans has a variety of PAMPs, such as
chitin, glucan, mannoproteins and glycolipids. These struc-
tures act as ligants for receptors that specifically recognize
these patterns, normally present on the surface of the host
cells. This host–fungal interaction exhibits features of a
dynamic system, in which the same cell can easily switch
between different morphological forms presenting different
PAMPs at different moments of time, thereby modulating the
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albicans.62–64 C. albicans has the ability to mask certain cell
wall components and unmask others, qualitatively changing
the PAMPs that are exposed to the host. For instance, dectin-1
recognizes b-glucans on fungal cell walls and triggers immune
responses by the production of pro and anti-inflammatory
cytokines. However, while the yeast form displays b-glucans on
its surface, the hyphal form shields its layer of b-glucans
underneath a coat of mannoproteins.65On the assumption that
C. albicans expresses molecules capable of binding to SLPI, flow
cytometry analysis was carried out. The results showed that the
cells were strongly recognized by the anti-hSLPI, in a dose-
dependent manner, suggesting the existence of binding sites for
this protein on the surface of C. albicans, which can contribute to
the construction of alternative models to manage infections
caused by this organism by blocking these sites.
Cell wall glycoconjugates have an important role in the
interaction between fungus and host cells.66 To evaluated the
effect of SLPI on the expression of cell surface mannoproteins
of C. albicans, this study used FITC labelled Concanavalin A due
to its ability to bind to mannose residues. The results showed
that treatment with 9.0 mM of SLPI was not enough to change
the availability of mannoproteins on the cell wall. However
treatment with the maximal physiologic concentration
(80 mM) reduced the binding of concanavalin A to the cell
surface by 20%, pointing to a possible reduction in the
expression of cell wall mannoproteins or a decreasing in
mannose residues available for the connection to the lectin. In
fact, con-A has been employed as a viable marker to evaluate
the expression of mannans and mannoproteins on the surface
of microorganisms.67 These structures have a key role not only
in maintaining the structural integrity of the cell, but also in
the process of adhesion to host cells.68,69 Thus, the possible
reduction in the expression of mannoproteins in C. albicans, as
suggested by treatment with 80 mM of SLPI indicates an
important potential on modulating one virulence factor that
can impair yeast adhesion to the epithelium. As previously
stated, fungal cell walls are complex, dynamic and highly
adaptable organelle. C. albicans alters the phenotype of its wall
by changing mannoproteins and polymer distribution in
response to environmental conditions. Hence, some authors
have already speculated that the variation in fungal cell wall
phenotypes may have important implications for host–
pathogen interactions.70
The effect of SLPI on the ultrastructure of C. albicans was
evaluated by TEM. Yeasts treated with 80 mM of SLPI revealed
cytoplasmatic deflation, and the presence of disorganized
plasmatic membrane like structures on the inner side of the
plasma membrane within the cytoplasm compartment. This
result suggests that the SLPI protein was able to overcome the
cell wall and interact with the cytoplasmic membrane or at
least interfere with the synthesis of its components. In fact, a
previous study has already reported structural changes in the
plasmatic membrane after the treatment of Cryptococcus
neoformans with inhibitors of the synthesis of ergosterol71
similar to this study.
In summary, the results obtained in this study point to the
possible application of SLPI as a viable alternative in the
treatment and management of infections caused by C. albicans,
since this inhibitor was able to exert an important influence onthe viability and on relevant virulence mechanisms of
C. albicans. Considering this, the exogenous administration
of this protein could perhaps become a viable therapeutic
alternative in the future, even for C. albicans resistant strains,
overcoming toxicity issues, considering its constitutive and
physiological features.
Funding
The authors would like to thank CAPES and CNPq (Brazil), and
FAPERJ (Rio de Janeiro, Brazil) for the financial support of this
research.
Competing interests
None declared.
Ethical approval
Not required.
r e f e r e n c e s
1. Pfaller MA, Diekema DJ. Epidemiology of invasive
candidiasis: a persistent public health problem. Clin
Microbiol Rev 2007;20:133–63.
2. Karkowska-Kuleta J, Rapala-Kozik M, Kozik A. Fungi
pathogenic to humans: molecular bases of virulence of
Candida albicans, Cryptococcus neoformans and Aspergillus
fumigatus. Acta Biochim Pol 2009;56:211–24.
3. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in
patients with haematologic malignancies and marrow/stem
cell transplant recipients. Semin Respir Infect 2002;17:113–20.
4. Odds FC, Gow NA, Brown AJ. Fungal virulence studies come
of age. Genome Biol 2001;2:1009.
5. Gulsham K, Moye-Rowley WS. Multidrug resistance in fungi.
Eukaryot Cell 2007;6:1933–42.
6. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic
drug monitoring for triazoles. Curr Opin Infect Dis
2008;21:580–6.
7. Petrikkos G, Skiada A. Recent advances in antifungal
chemotherapy. Int J Antimicrob Agents 2007;30:107–8.
8. Canuto MM, Rodero FG. Antifungal drug resistance to azole
and polyenes. Lancet Infect Dis 2002;2:550–63.
9. Odds FC. Should resistance to azole antifungals in vitro be
interpreted as predicting clinical non-response? Drug Resist
Updat 1998;1:11–5.
10. Cutler JE. Putative virulence factors of Candida albicans. Annu
Rev Microbiol 1991;45:187–218.
11. Odds FC. Pathogenesis of Candida infections. J Am Acad
Dermatol 1994;31:s2–5.
12. Portela MB, Kneipp LF, Ribeiro de Souza IP, Holandino C,
Alviano CS, Meyer-Fernandes JR, et al. Ectophosphatase
activity in Candida albicans influences fungal adhesion: study
between HIV-positive and HIV-negative isolates. Oral Dis
2010;16:431–7.
13. Kretschmar M, Hube B, Bertsch T, Sanglard D, Merker R,
Schro¨der M, et al. Germ tubes and proteinase activity
contribute to virulence of Candida albicans in murine
peritonitis. Infect Immun 1999;67:6637–42.
a r c h i v e s o f o r a l b i o l o g y 5 9 ( 2 0 1 4 ) 9 2 8 – 9 3 793614. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted
aspartyl proteinases in virulence and pathogenesis.
Microbiol Mol Biol Rev 2003;67:400–28.
15. Gauwerky K, Borelli C, Korting HC. Targeting virulence: a
new paradigm for antifungals. Drug Discov Today
2009;14:214–22.
16. Eisenberg SP, Hale KK, Heimdal P, Thompson RC. Location of
protease inhibitory region of secretory leucocyte protease
inhibitor. J Biol Chem 1990;256:7976–81.
17. Thompson RC, Ohlsson K. Isolation, properties, and
complete aminoacid sequence of human secretory
leucocyte protease inhibitor, a potent inhibitor of leucocyte
elastase. Proc Natl Acad Sci U S A 1986;83:6692–6.
18. Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau
T. The antibacterial and antifungal properties of trappin-2
(pre´-elafin) do not depend on its protease inhibitory
function. FEBS J 2008;275:2008–20.
19. Moreau T, Baranger K, Dade´ S, Dallet-Choisy S, Guyot N,
Zani ML. Multifaceted roles of human elafin and secretory
leucocyte´ protease inhibitor (SLPI), two serine protease
inhibitors of the chelonianin family. Biochimie 2008;90:
284–95.
20. Stetler G, Brewer MT, Thompson RC. Isolation and sequence
of a human gene encoding a potent inhibitor of leukocyte
proteases. Nucleic Acids Res 1986;14:7883–96.
21. Dietze SC, Sommerhoff CP, Fritz H. Inhibition of histamine
release from human mast cells ex vivo by natural and
synthetic chymase inhibitors. Biol Chem Hoppe-Seyler
1990;371(Suppl.):75–9.
22. Franken C, Meijer CJLM, Dijkman JH. Tissue distribution of
antileukoprotease and lysozyme in humans. J Histochem
Cytochem 1989;37:493–8.
23. Shugars DC, Watkins CA, Cowen HJ. Salivary concentration
of secretory leukocyte protease inhibitor, an antimicrobial
protein, is decreased with advanced age. Gerontology
2001;47:246–53.
24. Tjabringa GS, Vos JB, Olthuis D, Ninaber DK, Rabe KF,
Schalkwijk J, et al. Host defense effector molecules in
mucosal secretions. FEMS Immunol Med Microbiol
2005;45:151–8.
25. Nittayananta W, Kemapunmanus M, Yangngam S,
Talungchit S, Sriplung H. Expression of oral secretory
leukocyte protease inhibitor in HIV-infected subjects with
long-term use of antiretroviral therapy. Oral Pathol Med
2013;42:208–15.
26. Shugars DC. Endogenous mucosal antiviral factors of oral
cavity. J Infect Dis 1999;179:S431–5.
27. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB,
Greenwell-Wild T, et al. Secretory leukocyte protease
inhibitor mediates non-redundant functions necessary for
normal wound healing. Nat Med 2000;10:1147–53.
28. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, et al.
Conversion of proepithelin to epithelins: roles of SLPI and
elastase in host defense and wound repair. Cell
2002;111:867–78.
29. Moutsopoulos NM, Greenwell-Wild T, Wahl SM. Differential
mucosal susceptibility in HIV-1 transmission and infection.
Adv Dent Res 2006;19:52–6.
30. Moutsopoulos NM, Nares S, Nikitakis N, Rangel Z, Wen J,
Munson P, et al. Tonsil epithelial factors may influence
oropharyngeal human immunodeficiency virus
transmission. Am J Pathol 2007;171:571–9.
31. Tomee JF, Hiemstra PS, Heinzel-Wieland R, Kauffman HF.
Antileukoprotease: an endogenous protein in the innate
mucosal defense against fungi. J Infect Dis 1997;176:740–7.
32. Nishimura J, Saiga H, Sato S, Okuyama M, Kayama H,
Kuwata H, et al. Potent antimycobacterial activity of mouse
secretory leukocyte protease inhibitor. J Immunol
2008;180:4032–9.33. Diz Dios P, Ocampo A, Miralles C, Otero I, Iglesias I, Rayo N,
et al. Frequency of oropharyngeal candidiasis in HIV-
infected patients on protease inhibitor therapy. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 1999;87:437–41.
34. Melo NR, Taguchi H, Jorge J, Pedro RJ, Almeida OP,
Fukushima K, et al. Oral Candida flora from Brazilian human
immunodeficiency virus-infected patients in the highly
active antiretroviral therapy era. Mem Inst Oswaldo Cruz
2004;99:425–31.
35. Costa CR, Cohen AJ, Fernandes OF, Miranda KC, Passos XS,
Souza LK, et al. Asymptomatic oral carriage of Candida
species in HIV-infected patients in the highly active
antiretroviral therapy era. Rev Inst Med Trop 2006;48:257–61.
36. Cerqueira DF, Portela MB, Pomarico L, de Arau´ jo Soares RM,
de Souza IP, Castro GF. Oral Candida colonization and its
relation with predisposing factors in HIV-infected children
and their uninfected siblings in Brazil: the era of highly
active antiretroviral therapy. J Oral Pathol Med 2010;39:
188–94.
37. Hay RJ. The management of superficial candidiasis. J Am
Acad Dermatol 1999;40:S35–42.
38. Gu¨rcu¨og˘lu E, Ener B, Akalin H, Sinirtas¸ M, Evci C, Akc¸ag˘lar S,
et al. Epidemiology of nosocomial candidaemia in a
university hospital: a 12-year study. Epidemiol Infect
2010;138:1328–35.
39. Braga-Silva LA, dos Santos AL, Portela MB, Souto-Padro´n T,
de Arau´ jo Soares RM. Effect of Suramin on the human
pathogen Candida albicans: implications on the fungal
development and virulence. FEMS Immunol Med Microbiol
2007;51:399–406.
40. Garcia-Gomes AS, Curvelo JA, Soares RM, Ferreira-Pereira.
et al. Curcumin acts synergistically with fluconazole to
sensitize a clinical isolate of Candida albicans showing a MDR
phenotype. Med Mycol 2012;50:26–32.
41. Kamboj RC, Pal S, Raghav N, Singh H. A selective
colorimetric assay for cathepsin L using Z-Phe-Arg-4-
methoxy-beta-naphthylamide. Biochimie 1993;75:873–8.
42. Hazen KC, Hazen BW. A polystyrene microsphere assay for
detecting surface hydrophobicity variations within Candida
albicans populations. J Microbiol Methods 1987;6:289–99.
43. Willocks L, Leen CL, Brettle RP, Urquhart D, Russell TB,
Milne LJ, et al. Fluconazole resistance in AIDS patients. J
Antimicrob Chemother 1991;28:937–9.
44. NCCLS. Me´todo de Refereˆncia para Testes de Diluic¸a˜o em Caldo
para a Determinac¸a˜o da Sensibilidade a Terapia Antifu´ngica das
Leveduras; Norma Aprovada—Segunda Edic¸a˜o. NCCLS document
M27-A2. 940 West Valley Road, Suite 1400, Wayne,
Pennsylvania 19087-1898 Estados Unidos: NCCLS; 2002,
ISBN: 1-56238-469-4.
45. Tomee JF, Koe¨ter GH, Hiemstra PS, Kauffman HF, et al.
Secretory leucoprotease inhibitor: a native antimicrobial
protein presenting a new therapeutic option? Thorax
1998;53:114–6.
46. McElvaney NG, Nakamura H, Birrer P, He´bert CA, Wong WL,
Alphonso M, et al. Modulation of airway inflammation in
cystic fibrosis. J Clin Invest 1992;90:1296–301.
47. Gregori C. Cirurgia buco-dento-alveolar: Suporte medicamentoso
em cirurgia buco dento alveolar. 3rd ed. Sa¨o Paulo: Sarvier; 1996.
48. Newport G, Kuo A, Flattery A, Gill C, Blake JJ, Kurtz MB, et al.
Inactivation of Kex2p diminishes the virulence of Candida
albicans. J Biol Chem 2003;278:1713–20.
49. Hube B. Possible role of secreted proteinases in Candida
albicans infections. Rev Iberoam Micol 1998;15:65–8.
50. Rodrigues ML, dos Reis FC, Puccia R, Travassos LR, Alviano
CS, et al. Cleavage of human fibronectin and other
basement membrane-associated proteins by a Cryptococcus
neoformans serine proteinase. Microb Pathog 2003;34:65–71.
51. Casadevall A, Pirofski L. Host–pathogen interactions: the
attributes of virulence. J Infect Dis 2001;184:337–44.
a r c h i v e s o f o r a l b i o l o g y 5 9 ( 2 0 1 4 ) 9 2 8 – 9 3 7 93752. Ruiz-Herrera J, Elorza MV, Valentı´n E, Sentandreu R, et al.
Molecular organization of the cell wall of Candida albicans and
its relation to pathogenicity. FEMS Yeast Res 2006;6:14–29.
53. Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to
epithelins: roles of SLPI and elastase in host defense and
wound repair. Cell 2002;111:867–78.
54. Sun JN, Solis NV, Phan QT, Bajwa JS, Kashleva H, Thompson
A, et al. Host cell invasion and virulence mediated by
Candida albicans Ssa1. PLoS Pathog 2010;11:6.
55. Zakikhany K, Naglik JR, Schmidt-Westhausen A, Holland G,
Schaller M, Hube B, et al. In vivo transcript profiling of
Candida albicans identifies a gene essential for interepithelial
dissemination. Cell Microbiol 2007;9:2938–54.
56. Hazen KC, Hazen B. Dynamic expression of cell surface
hydrophobicity during initial yeast cell growth and before
germ tube formation of Candida albicans. Infect Immun
1998;56:2521–5.
57. Imbert C, Rodier MH, Daniault G, Jacquemin JL. Influence of
sub-inhibitory concentrations of conventional antifungals
on metabolism of Candida albicans and on its adherence to
polystyrene and extracellular matrix proteins. Med Mycol
2002;40:123–9.
58. Blanco MT, Sacrista´n B, Bateta A, Ferna´ndez-Caldero´n MC,
Hurtado C, Pe´rez-Giraldo C, et al. Cellular surface
hydrophobicity as an additional phenotypic criterion
applied to differentiate strains of Candida albicans and
Candida dubliniensis. Diagn Microbiol Infect Dis 2008;60:129–31.
59. Hazen KC. Relationship between expression of cell surface
hydrophobicity protein 1 (CSH1p) and surface
hydrophobicity properties of Candida dubliniensis. Curr
Microbiol 2004;48:447–51.
60. Singleton DR, Masuoka J, Hazen KC. Cloning and analysis of
a Candida albicans gene that affects cell surface
hydrophobicity. J Bacteriol 2001;183:3582–8.
61. Ellepola AN, Joseph BK, Khan ZU. Changes in germ tube
formation and cell-surface hydrophobicity of oral Candidadubliniensis isolates following brief exposure to sub-cidal
concentrations of polyene and azole antifungal agents.
Mycoses 2013;56:463–70.
62. Cottier F, Pavelka N. Complexity and dynamics of host–
fungal interactions. Immunol Res 2012;53:127–35.
63. Villar CC, Dongari-Bagtzoglou A. Immune defence
mechanisms and immunoenhancement strategies in
oropharyngeal candidiasis. Expert Rev Mol Med 2008;13:29.
64. Netea MG, Brown GD, Kullberg BJ, Gow NA, et al. An
integrated model of the recognition of Candida albicans by
the innate immune system. Nat Rev Microbiol 2008;6:67–78.
65. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M,
Findon H, et al. Dectin-1 is required for beta-glucan
recognition and control of fungal infection. Nat Immunol
2007;8:31–8.
66. Pietrella D, Bistoni G, CorbuccI C, Perito S, Vecchiarelli A,
et al. Candida albicans mannoprotein influences the
biological function of dendritic cells. Cell Microbiol
2006;8:602–12.
67. d’Avila-Levy CM, Arau´ jo FM, Vermelho AB, Branquinha MH,
Alviano CS, Soares RM, et al. Differential lectin recognition
of glycoproteins in choanomastigote-shaped
trypanossomatids: taxonomic implications. FEMS Microbiol
Lett 2004;231:171–6.
68. Warolin J, Essmann M, Larsen B. Flow cytometry of Candida
albicans for investigations of surface marker expression and
phagocytosis. Ann Clin Lab Sci 2005;35:302–11.
69. Chaffin WLJ. Candida albicans cell wall proteins. Microbiol Mol
Biol Rev 2008;72:495–544.
70. Kruppa M, Greene RR, Noss I, Lowman DW, Williams DL.
C. albicans increases cell wall mannoprotein, but not
mannan, in response to blood, serum and cultivation at
physiological temperature. Glycobiology 2011;21:1173–80.
71. Guerra CR, Ishida K, Nucci M, Rozental S. Terbinafine
inhibits Cryptococcus neoformans growth and modulates
fungal morphology. Mem Inst Oswaldo Cruz 2012;107:582–90.
